Evidence map›Paper›PMID 41807048›Full record

ArticleLife science alliance2026

The APOL1 variant p.N264K is predicted to block ion flow by occluding a pore at the cell surface.

Verena Höffken, Lara Console, Niklas Nelde, Hermann Pavenstädt, Cesare Indiveri, Thomas Weide

Abstract read
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Apolipoproteins L involvement in immunity.Journal of human immunity · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Verena HöffkenUniversity Hospital of Münster, Medical Clinic D, Münster, Germany.ORCID 0000-0003-1689-5462
Lara ConsoleDepartment BEST (Biologia, Ecologia, Scienze della Terra), University of Calabria, Arcavacata CS, Italy.ORCID 0000-0002-0238-0946
Niklas NeldeUniversity Hospital of Münster, Medical Clinic D, Münster, Germany.
Hermann PavenstädtUniversity Hospital of Münster, Medical Clinic D, Münster, Germany.
Cesare IndiveriDepartment BEST (Biologia, Ecologia, Scienze della Terra), University of Calabria, Arcavacata CS, Italy.ORCID 0000-0001-9818-6621
Thomas WeideUniversity Hospital of Münster, Medical Clinic D, Münster, Germany weidet@uni-muenster.de Thomas.Weide@ukmuenster.de.ORCID 0000-0002-2707-665X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The APOL1 gene variants G1 and G2 are associated with an increased risk of APOL1-mediated kidney disease. A recently identified variant, p.N264K (M1), mitigates this risk of renal damage by abolishing APOL1-G2's associated cytotoxicity. However, the molecular and structural basis of this protective effect remains incompletely understood. In this study, we first show that both the cytotoxic G2 and the nontoxic M1-G2 exhibit similar intracellular localization, surface expression, and turnover kinetics. Moreover, N-glycosylation assays indicated no differences in topology, and 3D models demonstrated that both cytotoxic G2 and nontoxic APOL1 M1-G2 span the membrane four times, forming a potential ion channel. Interestingly, molecular dynamics analyses of a computational APOL1 3D model further revealed that in case of M1, the lysine at position 264 occludes this channel, thereby preventing ion pore activity of APOL1. These findings provide, for the first time, a mechanistic explanation for the nontoxic behavior of the APOL1 M1-G2 variant. Additional 3D analyses suggest that the C-terminal region may contribute to APOL1 multimerization, potentially influencing ion flux and cytotoxicity.

Indexed as

Apolipoprotein L1Cell MembraneAnimalsGlycosylationHEK293 CellsHumansIon ChannelsMolecular Dynamics SimulationAPOL1 protein, humanApolipoprotein L1Ion Channels

Identifiers

PMID41807048
PMCPMC12976425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.